Mycobacterium abscessus subsp abscessus lung disease: 'trouble ahead, trouble behind...'

F1000Prime Reports

Volumn 6, Issue , 2014, Pages

  Griffith, David E ^a  

^a UNIVERSITY OF TEXAS HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; CEFOXITIN; CIPROFLOXACIN; CLARITHROMYCIN; DOXYCYCLINE; LINEZOLID; TIGECYCLINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; HUMAN; LUNG DISEASE; LUNG INFECTION; MYCOBACTERIOSIS; MYCOBACTERIUM ABSCESSUS; NONHUMAN; TAXONOMY;

MYCOBACTERIUM ABSCESSUS;

EID: 84912053711     PISSN: 20517599     EISSN: 20517599     Source Type: Journal    
DOI: 10.12703/P6-107     Document Type: Article

References (26)

1. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, Holland SM, Horsburgh R, Huitt G, Iademarco MF, Iseman M, Olivier K, Ruoss S, von Reyn, C Fordham, Wallace RJ, Winthrop K: An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007, 175:367-416.
2. Griffith DE, Girard WM, Wallace RJ: Clinical features of pulmonary disease caused by rapidly growing mycobacteria. An analysis of 154 patients. Am Rev Respir Dis 1993, 147:1271-8.
3. Park S, Suh GY, Chung MP, Kim H, Kwon OJ, Lee KS, Lee NY, Koh W: Clinical significance of Mycobacterium fortuitum isolated from respiratory specimens. Respir Med 2008, 102:437-42.
4. Nash KA, Zhang Y, Brown-Elliott BA, Wallace RJ: Molecular basis of intrinsic macrolide resistance in clinical isolates of Mycobacterium fortuitum. J Antimicrob Chemother 2005, 55:170-7.
5. Nash KA, Brown-Elliott BA, Wallace RJ: A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. Antimicrob Agents Chemother 2009, 53:1367-76.
6. Kirschner P, Rosenau J, Springer B, Teschner K, Feldmann K, Böttger EC: Diagnosis of mycobacterial infections by nucleic acid amplification: 18-month prospective study. J Clin Microbiol 1996, 34:304-12.
7. Adékambi T, Berger P, Raoult D, Drancourt M: rpoB gene sequencebased characterization of emerging non-tuberculous mycobacteria with descriptions of Mycobacterium bolletii sp. nov., Mycobacterium phocaicum sp. nov. and Mycobacterium aubagnense sp. nov. Int J Syst Evol Microbiol 2006, 56:133-43.
8. Adékambi T, Reynaud-Gaubert M, Greub G, Gevaudan M, La Scola B, Raoult D, Drancourt M: Amoebal coculture of 'Mycobacterium massiliense' sp. nov. from the sputum of a patient with hemoptoic pneumonia. J Clin Microbiol 2004, 42:5493-501.
9. Bastian S, Veziris N, Roux A, Brossier F, Gaillard J, Jarlier V, Cambau E: Assessment of clarithromycin susceptibility in strains belonging to the Mycobacterium abscessus group by erm(41) and rrl sequencing. Antimicrob Agents Chemother 2011, 55:775-81.
10. Leao SC, Tortoli E, Euzéby JP, Garcia MJ: Proposal that Mycobacterium massiliense and Mycobacterium bolletii be united and reclassified as Mycobacterium abscessus subsp. bolletii comb. nov., designation of Mycobacterium abscessus subsp. abscessus subsp. nov. and emended description of Mycobacterium abscessus. Int J Syst Evol Microbiol 2011, 61:2311-3.
11. Tettelin H, Davidson RM, Agrawal S, Aitken ML, Shallom S, Hasan NA, Strong M, de Moura Vinicius Calado Nogueira, De Groote, Mary Ann, Duarte RS, Hine E, Parankush S, Su Q, Daugherty SC, Fraser CM, Brown-Elliott BA, Wallace RJ, Holland SM, Sampaio EP, Olivier KN, Jackson M, Zelazny AM: High-level relatedness among Mycobacterium abscessus subsp. massiliense strains from widely separated outbreaks. Emerging Infect Dis 2014, 20:364-71.
12. van Ingen J, Boeree MJ, van Soolingen D, Mouton JW: Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria. Drug Resist Updat 2012, 15:149-61.
13. van Ingen J, Boeree MJ, van Soolingen D, Iseman MD, Heifets LB, Daley CL: Are phylogenetic position, virulence, drug susceptibility and in vivo response to treatment in mycobacteria interrelated? Infect Genet Evol 2012, 12:832-7.
14. Maurer FP, Rüegger V, Ritter C, Bloemberg GV, Böttger EC: Acquisition of clarithromycin resistance mutations in the 23S rRNA gene of Mycobacterium abscessus in the presence of inducible erm(41). J Antimicrob Chemother 2012, 67:2606-11.
15. Jarand J, Levin A, Zhang L, Huitt G, Mitchell JD, Daley CL: Clinical and microbiologic outcomes in patients receiving treatment for Mycobacterium abscessus pulmonary disease. Clin Infect Dis 2011, 52:565-71.
16. Jeon K, Kwon OJ, Lee NY, Kim B, Kook Y, Lee S, Park YK, Kim CK, Koh W: Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients. Am J Respir Crit Care Med 2009, 180:896-902.
17. Harada T, Akiyama Y, Kurashima A, Nagai H, Tsuyuguchi K, Fujii T, Yano S, Shigeto E, Kuraoka T, Kajiki A, Kobashi Y, Kokubu F, Sato A, Yoshida S, Iwamoto T, Saito H: Clinical and microbiological differences between Mycobacterium abscessus and Mycobacterium massiliense lung diseases. J Clin Microbiol 2012, 50:3556-61.
18. Koh W, Jeon K, Lee NY, Kim B, Kook Y, Lee S, Park YK, Kim CK, Shin SJ, Huitt GA, Daley CL, Kwon OJ: Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus. Am J Respir Crit Care Med. 2011, 183:405-10.
19. Choi G, Shin SJ, Won C, Min K, Oh T, Hahn M, Lee K, Lee SH, Daley CL, Kim S, Jeong B, Jeon K, Koh W: Macrolide treatment for Mycobacterium abscessus and Mycobacterium massiliense infection and inducible resistance. Am J Respir Crit Care Med 2012, 186:917-25.
20. Maurer FP, Castelberg C, Quiblier C, Böttger EC, Somoskövi A: Erm (41)-dependent inducible resistance to azithromycin and clarithromycin in clinical isolates of Mycobacteriumabscessus. J Antimicrob Chemother 2014, 69:1559-63.
21. Wallace RJ, Brown-Elliott BA, Ward SC, Crist CJ, Mann LB, Wilson RW: Activities of linezolid against rapidly growing mycobacteria. Antimicrob Agents Chemother 2001, 45:764-7.
22. Wallace RJ, Brown-Elliott BA, Crist CJ, Mann L, Wilson RW: Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria. Antimicrob Agents Chemother 2002, 46:3164-7.
23. Wallace RJ, Dukart G, Brown-Elliott BA, Griffith DE, Scerpella EG, Marshall B: Clinical experience in 52 patients with tigecyclinecontaining regimens for salvage treatment of Mycobacterium abscessus and Mycobacterium chelonae infections. J Antimicrob Chemother 2014, 69:1945-53.
24. Lee M, Lee J, Carroll MW, Choi H, Min S, Song T, Via LE, Goldfeder LC, Kang E, Jin B, Park H, Kwak H, Kim H, Jeon H, Jeong I, Joh JS, Chen RY, Olivier KN, Shaw PA, Follmann D, Song SD, Lee J, Lee D, Kim CT, Dartois V, Park S, Cho S, Barry CE: Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med 2012, 367:1508-18.
25. Maurer FP, Bruderer VL, Ritter C, Castelberg C, Bloemberg GV, Böttger EC: Lack of Antimicrobial Bactericidal Activity in Mycobacterium abscessus. Antimicrob Agents Chemother 2014, 58:3828-36.
26. Andries K, Verhasselt P, Guillemont J, Göhlmann, Hinrich WH, Neefs J, Winkler H, van Gestel J, Timmerman P, Zhu M, Lee E, Williams P, Chaffoy D de, Huitric E, Hoffner S, Cambau E, Truffot-Pernot C, Lounis N, Jarlier V: A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005, 307:223-7.